Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know

  • Braschi-Amirfarzan, Marta (Department of Radiology, Brigham and Women's Hospital and Dana Farber Cancer Institute) ;
  • Tirumani, Sree Harsha (Department of Radiology, Brigham and Women's Hospital and Dana Farber Cancer Institute) ;
  • Hodi, Frank Stephen Jr. (Department of Medical Oncology and Medicine, Dana Farber Cancer Institue) ;
  • Nishino, Mizuki (Department of Radiology, Brigham and Women's Hospital and Dana Farber Cancer Institute)
  • Received : 2016.08.10
  • Accepted : 2016.09.11
  • Published : 2017.01.01
⟨ Previous Next ⟩

Abstract

Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1 and PD-L2). Response to immune-checkpoint inhibitors is evaluated on imaging using the immune-related response criteria. Activation of immune system results in a unique toxicity profile termed immune-related adverse events. This article will review the molecular mechanism, clinical applications, imaging of immune-related response patterns and adverse events associated with immune-checkpoint inhibitors.

Keywords

References

  1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723 https://doi.org/10.1056/NEJMoa1003466
  2. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 1984;68:233-255
  3. Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 2016;5:e1163462 https://doi.org/10.1080/2162402X.2016.1163462
  4. Yoo S, Choi SY, You D, Kim CS. New drugs in prostate cancer. Prostate Int 2016;4:37-42 https://doi.org/10.1016/j.prnil.2016.05.001
  5. Chen Y, Liu D. Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy. Stem Cell Investig 2014;1:2
  6. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034 https://doi.org/10.1084/jem.192.7.1027
  7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736 https://doi.org/10.1126/science.271.5256.1734
  8. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987;328:267-270 https://doi.org/10.1038/328267a0
  9. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911 https://doi.org/10.1126/science.7694363
  10. Calabro L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015;3:301-309 https://doi.org/10.1016/S2213-2600(15)00092-2
  11. Hodi FS, Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol 2008;5:696-697 https://doi.org/10.1038/ncponc1259
  12. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164 https://doi.org/10.1016/S1470-2045(09)70334-1
  13. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895 https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
  14. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030 https://doi.org/10.1200/JCO.2013.53.0105
  15. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117 https://doi.org/10.1016/S0140-6736(14)60958-2
  16. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144 https://doi.org/10.1056/NEJMoa1305133
  17. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res 2016 May 11 [Epub]. http://dx.doi.org/10.1158/1078-0432.CCR-15-2839
  18. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016;34:2980-2987 https://doi.org/10.1200/JCO.2016.66.9929
  19. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015;125:3393-3400 https://doi.org/10.1182/blood-2015-02-567453
  20. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-319 https://doi.org/10.1056/NEJMoa1411087
  21. Perales MA, Sauter CS, Armand P. Fast cars and no brakes: autologous stem cell transplantation as a platform for novel immunotherapies. Biol Blood Marrow Transplant 2016;22:17-22 https://doi.org/10.1016/j.bbmt.2015.10.014
  22. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34:2690-2697 https://doi.org/10.1200/JCO.2016.66.4482
  23. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib Study. J Clin Oncol 2016;34:2698-2704 https://doi.org/10.1200/JCO.2015.65.9789
  24. Armand P. Checkpoint blockade in lymphoma. Hematology Am Soc Hematol Educ Program 2015;2015:69-73 https://doi.org/10.1182/asheducation-2015.1.69
  25. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016;375:143-153 https://doi.org/10.1056/NEJMoa1601202
  26. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016 Jun 27 [Epub]. http://dx.doi.org/10.1200/JCO.2016.67.3467
  27. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-1920 https://doi.org/10.1016/S0140-6736(16)00561-4
  28. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598 https://doi.org/10.1158/1078-0432.CCR-09-1024
  29. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133 https://doi.org/10.1056/NEJMoa1302369
  30. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-7420 https://doi.org/10.1158/1078-0432.CCR-09-1624
  31. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 2011;197:W241-W246 https://doi.org/10.2214/AJR.10.6032
  32. Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 2015;35:424-437 https://doi.org/10.1148/rg.352140121
  33. Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 2015;84:1259-1268 https://doi.org/10.1016/j.ejrad.2015.03.017
  34. Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40 https://doi.org/10.1186/s40425-014-0040-2
  35. Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2014;2:17 https://doi.org/10.1186/2051-1426-2-17
  36. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013;19:3936-3943 https://doi.org/10.1158/1078-0432.CCR-13-0895
  37. Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. J Immunother Cancer 2016;4:30 https://doi.org/10.1186/s40425-016-0134-0
  38. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-2582 https://doi.org/10.1200/JCO.2003.01.144
  39. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol 2011;18:54-62 https://doi.org/10.1016/j.acra.2010.08.021
  40. Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 2009;252:263-272 https://doi.org/10.1148/radiol.2522081593
  41. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  42. Zhao B, Tan Y, Bell DJ, Marley SE, Guo P, Mann H, et al. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol 2013;82:959-968 https://doi.org/10.1016/j.ejrad.2013.02.018
  43. Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 2014;271:6-27 https://doi.org/10.1148/radiol.14122524
  44. Bohnsack O, Ludajic K, Hoos A. Adaptation of the immune-related response criteria: irRECIST. Massachusetts: ESMO 2014 Abstract 4958
  45. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 https://doi.org/10.1093/jnci/92.3.205
  46. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
  47. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010;195:281-289 https://doi.org/10.2214/AJR.09.4110
  48. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012;198:737-745 https://doi.org/10.2214/AJR.11.7483
  49. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016;34:1510-1517 https://doi.org/10.1200/JCO.2015.64.0391
  50. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015;3:1185-1192 https://doi.org/10.1158/2326-6066.CIR-15-0102
  51. Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 2016;4:289-293 https://doi.org/10.1158/2326-6066.CIR-15-0267
  52. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015;373:288-290 https://doi.org/10.1056/NEJMc1505197
  53. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197:W992-W1000 https://doi.org/10.2214/AJR.10.6198
  54. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 2013;200:W468-W474 https://doi.org/10.2214/AJR.12.9751
  55. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 2011;68:1099-1109 https://doi.org/10.1007/s00280-011-1737-2
  56. Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013;31:1071-1077 https://doi.org/10.1007/s10637-013-9939-6
  57. Gonzalez-Rodriguez E, Rodriguez-Abreu D2; Spanish Group for Cancer Immuno-Biotherapy (GETICA). Oncologist 2016;21:804-816 https://doi.org/10.1634/theoncologist.2015-0509
  58. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 2009;30:1751-1753 https://doi.org/10.3174/ajnr.A1623
  59. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009;218:69-70 https://doi.org/10.1159/000161122
  60. Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012;30:e156-e159 https://doi.org/10.1200/JCO.2011.39.3298
  61. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009;36:518-520 https://doi.org/10.1017/S0317167100007939
  62. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-2697 https://doi.org/10.1200/JCO.2012.41.6750
  63. Howard SA, Krajewski KM, Jagannathan JP, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, et al. A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. AJR Am J Roentgenol 2016;207:4-14 https://doi.org/10.2214/AJR.15.15480

Cited by

  1. Unerwünschte Wirkungen der Immuntherapie : Klinik, radiologische und nuklearmedizinische Befunde vol.57, pp.10, 2017, https://doi.org/10.1007/s00117-017-0285-0
  2. Advancing Immune and Cell-Based Therapies Through Imaging vol.19, pp.3, 2017, https://doi.org/10.1007/s11307-017-1069-7
  3. Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy vol.5, pp.11, 2017, https://doi.org/10.1007/s40134-017-0256-2
  4. Immune-related tumour response assessment criteria: a comprehensive review vol.91, pp.1084, 2017, https://doi.org/10.1259/bjr.20170457
  5. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency vol.23, pp.12, 2018, https://doi.org/10.1634/theoncologist.2018-0163
  6. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  7. Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy vol.8, pp.1, 2019, https://doi.org/10.4103/sajc.sajc_167_18
  8. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features vol.11, pp.3, 2017, https://doi.org/10.3390/cancers11030305
  9. Atypical Response Patterns in Patients Treated With Nivolumab vol.212, pp.6, 2017, https://doi.org/10.2214/ajr.18.20938
  10. A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies vol.213, pp.5, 2017, https://doi.org/10.2214/ajr.19.21135
  11. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  12. Imaging of Metastatic Germ Cell Tumors in Male Patients From Initial Diagnosis to Treatment-Related Toxicities: A Primer for Radiologists vol.214, pp.1, 2017, https://doi.org/10.2214/ajr.19.21623
  13. Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy vol.10, pp.4, 2020, https://doi.org/10.3390/diagnostics10040216
  14. Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists vol.45, pp.9, 2017, https://doi.org/10.1007/s00261-020-02531-5
  15. A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy-Related Toxicity: A Primer for the Radiologist vol.215, pp.3, 2020, https://doi.org/10.2214/ajr.20.22837
  16. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis vol.22, pp.4, 2021, https://doi.org/10.3348/kjr.2020.0728
  17. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography vol.94, pp.1118, 2021, https://doi.org/10.1259/bjr.20200663
  18. Radiological assessment of response and adverse events associated with novel systemic oncological therapies vol.76, pp.4, 2017, https://doi.org/10.1016/j.crad.2020.10.018